Consumer Healthcare giant, Haleon, recently spun out of GSK plc has reported strong growth in their third quarter trading update and raised their guidance for the full year slightly. They now see organic revenue growth of 8.0- 8.5%% for the full year and for margins to be slightly improved, despite some additional currency impacts.
Haleon saw improved trading in their Oral Health category, where their Sensodyne brand has a leading position. Respiratory health products have benefited from the seasonal bugs that are going around. Their only weak spot was Vitamins, Minerals and Supplements which was up against tough prior year comparables.
Subscribe
Gain access to all our Premium Content on FintechZoomPRO.More than 400+ articles, Daily updates, Real-time data, Better research, Advanced analytics.
